Gastroenterology -Therapeutics & Hepatology

Viral Hepatitis: New Treatment Paradigms

Viral hepatitis, encompassing types A, B, C, and E, has seen transformative advancements in treatment paradigms, enhancing patient outcomes and expanding therapeutic options. For hepatitis C, direct-acting antivirals (DAAs) have revolutionized treatment, offering cure rates exceeding 95% with shorter, more tolerable regimens. Newer DAAs and combination therapies are further improving efficacy and addressing diverse genotypes. In hepatitis B management, novel antiviral medications, such as tenofovir alafenamide and entecavir, are offering improved efficacy and reduced side effects. Research into therapeutic vaccines and immune-modulating agents aims to enhance viral clearance and prevent disease progression. For hepatitis E, which remains under-studied, emerging research is focusing on antiviral agents and vaccine development to address the growing recognition of its impact, particularly in pregnant women. Overall, these new treatment paradigms are shifting hepatitis management from chronic disease control to potential cure, with ongoing research paving the way for even more effective and personalized therapeutic strategies.